论文部分内容阅读
[目的]探讨华蟾素片、爱必妥注射液联合化疗治疗中晚期非小细胞肺癌(NSCLC)患者的临床疗效及对存活质量的影响.[方法]将73例中晚期NSCLC患者随机分为两组,对照组采取TP(紫杉醇+顺铂)方案化疗,观察组在对照组基础上加以华蟾素片、爱必妥注射液治疗,比较两组近期疗效、不良反应、治疗前后相关情况变化.[结果]观察组总有效率为59.46％(22/37),显著高于对照组的33.33％(12/36)(P＜0.05),而两组疾病控制率相比较差异无显著性(P＞0.05);观察组治疗后血清白介素-6(IL-6)、IL-10、CA125、癌胚抗原(CEA)、血管内皮生长因子(VEGF)水平均显著低于,IL-17、肿瘤坏死因子-α(TNF-α)水平显著高于对照组(P＜0.05);观察组存活质量改善率为48.65％(18/37)显著高于对照组的25.00％(9/36)(P＜0.05);观察组恶心呕吐、白细胞减少、贫血总发生率均低于对照组(P＜0.05).[结论]华蟾素片、爱必妥注射液联合TP化疗能有效提高中晚期NSCLC患者近期疗效,增强其免疫功能,显著改善其存活质量,减少不良反应.“,”[Objective] to investigate the clinical efficacy and quality of life of patients with advanced non small cell lung cancer (NSCLC) treated with Cinobufacini tablets and Erbitux injection combined TP chemotherapy.[Methods] Seventy-three cases of patients with advanced NSCLC were divided into the observation group(group A) and the control group(group B).The group B was treated with TP (paclitaxel and cisplatin)chemotherapy,and the group A was treated with cinobufacini tablets and Erbitux injection on the basis of treatment in the group B.The short-term efficacy,adverse reactions,and related changes before and after treatment were compared between the two groups.[Results]The total effective rate of the observation group was 59.46％ (22/37),which was significantly higher than 33.33％ (12/36) of the control group (P ＜0.05),but there was no significant difference in the disease control rate between the two groups (P ＞0.05);the levels of serum interleukin-6 (IL-6),IL-10,CA125,carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) in the observation group were significantly lower than those in the observation group after treatment;IL-17,TNF-αlevel was significantly higher than that of the control group,and the difference was significant (P ＜0.05);the improvement rate of survival quality in the observation group was 48.65％ (18/37),which was significantly higher than 25％ (9/36) in the control group (P ＜ 0.05);the incidence of nausea and vomiting,white blood cell reduction and anemia in the observation group were lower than those in the control group (P ＜0.05).[Conclusion] Cinobufacini tablets,Erbitux injection combined with TP chemotherapy can effectively improve the short-term efficacy,regulate immune abnormalities,enhance immune function,and significantly improve the quality of life in patients with advanced NSCLC.